Peter van Veldhuizen, MD
Hematology & Oncology · Wyoming, MINPI 1336163138
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,154 of the $1,314 with a category attached, or 87.8%. Sanofi accounts for 87.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,194 and has fallen 94.8% since, to $62 in 2024. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 6 payments — averaging $218.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- E.r. Squibb & Sons, L.L.C.$62
- Genentech, Inc.$57
- Pfizer$15
- Eisai Inc.$13
- Exelixis Inc.$12
Across 122 payments — averaging $5783.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$203K
- E.r. Squibb & Sons, L.L.C.$183K
- Roche Products Limited$126K
- Clovis Oncology, Inc.$83K
- Exelixis Inc.$46K
- Genentech, Inc.$32K
- plus $33K from 4 others
What the payments were for
- Speaking & faculty fees$1,15488%
- Food & beverage$13510%
- Education$252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $1,154 |
| E.r. Squibb & Sons, L.L.C. | 1 | $62 |
| Genentech, Inc. | 1 | $57 |
| Pfizer | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Exelixis Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$1,154
How this compares
$1,314 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 37 | $935,571 |
| Abiraterone Acetate | 52 | $232,131 |
| OrgovyxRelugolix | 15 | $38,280 |
| Prochlorperazine Maleate | 64 | $843 |
| Bicalutamide | 26 | $523 |
| Ondansetron Hcl | 68 | $359 |
| Dexamethasone | 11 | $340 |
| Oxycodone Hcl | 13 | $258 |
| Prednisone | 44 | $227 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $125 |
| Olanzapine | 57 | $63 |
| Gabapentin | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $12 | $935,57137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Wyoming
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.